98%
921
2 minutes
20
Unlabelled: Both metabolic and heamodynamic disorders accompany diabetes. Inadequate control of glycaemia, glication proteins and oxidative stress causes chronic thromboembolic and atherothrombosis complications. Disorders which are observed in diabetes induce intravascular platelets activation and changes with platelets' morphologic parameters. It is interesting if this process depends on glycaemic control diabetes? The aim of our study was to investigate in patients with type 2 diabetes the level of beta-thromboglobulin as the platelets activation marker and platelet count (PLT), mean platelet volume (MPV), which depend on diabetes control.
Material And Methods: The study group included 58 patients with type 2 diabetes (middle ages was 58) with long-term anamnesis and treated only with insulin. The control group was composed by 36 healthy people (middle ages was 54). The study group was categorized into two subgroups, in depending on percent of glycosylated haemoglobin (HbA1c) which is a marker of diabetes control: B1--HbA1c < 7,5%--(13 people), B2--HbA1c > or = 7,5%--(45 people). Identical set research (beta-TG, PLT MPV and HbA1c) were carried out in both study group and the control group. Blood samples were collected from elbow vein, with no staza use and were put to test- tubes with disodium versenate (EDTA-K2) and to vacuum test- tubes Vacutainer with anticoagulant CTAD.
Results: We didn't observe significantly important differences in the research parameters: B-TG, MPV and PLT between subgroups with good diabetes control and worse diabetes control. The level of beta-thromboglobulin and the mean platelet volume was significantly important higher in the study group than in the control subjects. However, PLT--platelet count, in the blood collected from patients with type 2 diabetes was slightly lower than in the control group.
Conclusion: Increased activation of platelets in patients with type 2 diabetes does not depend on glycaemic control diabetes.
Download full-text PDF |
Source |
---|
JAMA Netw Open
September 2025
Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Importance: As obesity rates rise in the US, managing associated metabolic comorbidities presents a growing burden to the health care system. While bariatric surgery has shown promise in mitigating established metabolic conditions, no large studies have quantified the risk of developing major obesity-related comorbidities after bariatric surgery.
Objective: To identify common metabolic phenotypes for patients eligible for bariatric surgery and to estimate crude and adjusted incidence rates of additional metabolic comorbidities associated with bariatric surgery compared with weight management program (WMP) alone.
JAMA Netw Open
September 2025
Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Importance: Patients with advanced cancer frequently receive broad-spectrum antibiotics, but changing use patterns across the end-of-life trajectory remain poorly understood.
Objective: To describe the patterns of broad-spectrum antibiotic use across defined end-of-life intervals in patients with advanced cancer.
Design, Setting, And Participants: This nationwide, population-based, retrospective cohort study used data from the South Korean National Health Insurance Service database to examine broad-spectrum antibiotic use among patients with advanced cancer who died between July 1, 2002, and December 31, 2021.
J Behav Med
September 2025
Center for Indigenous Health, Johns Hopkins University, Duluth, MN, USA.
Indigenous Peoples experience the highest age-adjusted prevalence of type 2 diabetes of any racial group in the U.S. Though the management of type 2 diabetes requires regular healthcare visits, North American Indigenous individuals with diabetes do not always utilize the healthcare available to them, and this lack of utilization may lead to poor health outcomes over time.
View Article and Find Full Text PDFDermatol Ther (Heidelb)
September 2025
Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Massarenti 9, 40138, Bologna, Bologna, Italy.
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have gained prominence for their efficacy in treating type 2 diabetes and obesity. Recent evidence suggests that their pleiotropic effects-beyond glycemic control and weight loss-include anti-inflammatory, immunomodulatory, and antioxidative effects, which may beneficially support various dermatologic conditions such as psoriasis, hidradenitis suppurativa, acanthosis nigricans, and Hailey-Hailey disease. However, GLP-1 RAs are also associated with emerging cutaneous adverse drug reactions, including bullous, exanthematous and vasculitic manifestations, and other rare side effects.
View Article and Find Full Text PDFJ Neurooncol
September 2025
Division of Neurosurgery, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Tottori, Japan.
Purpose: This study aimed to evaluate the prognostic significance of microvessel density (MVD), assessed by CD34 immunohistochemistry (IHC), and its correlation with radiological features and bevacizumab (BEV) treatment efficacy in newly diagnosed glioblastoma.
Methods: We retrospectively analyzed 41 patients with newly diagnosed glioblastoma. MVD was quantified using CD34 IHC, and patients were stratified into low and high MVD groups according to the cutoff value determined by receiver operating characteristic curve analysis (sensitivity, 76.